FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2071299041> ?p ?o ?g. }

• W2071299041 endingPage "460" @default.
• W2071299041 startingPage "453" @default.
• W2071299041 abstract "Uric acid is an antioxidant with neuroprotective effects in experimental models of stroke. We assessed whether uric acid therapy would improve functional outcomes at 90 days in patients with acute ischaemic stroke.URICO-ICTUS was a randomised, double-blind, placebo-controlled, phase 2b/3 trial that recruited patients with acute ischaemic stroke admitted to ten Spanish stroke centres. Patients were included if they were aged 18 years or older, had received alteplase within 4·5 h of symptom onset, and had an eligible National Institutes of Health Stroke Scale (NIHSS) score (>6 and ≤25) and premorbid (assessed by anamnesis) modified Rankin Scale (mRS) score (≤2). Patients were randomly allocated (1:1) to receive uric acid 1000 mg or placebo (both infused intravenously in 90 min during the infusion of alteplase), stratified by centre and baseline stroke severity. The primary outcome was the proportion of patients with excellent outcome (ie, an mRS score of 0-1, or 2 if premorbid score was 2) at 90 days, analysed in the target population (all randomly assigned patients who had been correctly diagnosed with ischaemic stroke and had begun study medication). The study is registered with ClinicalTrials.gov, number NCT00860366.Between July 1, 2011, and April 30, 2013, we randomly assigned 421 patients, of whom 411 (98%) were included in the target population (211 received uric acid and 200 received placebo). 83 (39%) patients who received uric acid and 66 (33%) patients who received placebo had an excellent outcome (adjusted risk ratio 1·23 [95% CI 0·96-1·56]; p=0·099). No clinically relevant or statistically significant differences were reported between groups with respect to death (28 [13%] patients who received uric acid vs 31 [16%] who received placebo), symptomatic intracerebral haemorrhage (nine [4%] vs six [3%]), and gouty arthritis (one [<1%] vs four [2%]). 516 adverse events occurred in the uric acid group and 532 in the placebo group, of which 61 (12%) and 67 (13%), respectively, were serious adverse events (p=0·703).The addition of uric acid to thrombolytic therapy did not increase the proportion of patients who achieved excellent outcome after stroke compared with placebo, but it did not lead to any safety concerns.Institute of Health Carlos III of the Spanish Ministry of Health and Fundación Doctor Melchor Colet." @default.
• W2071299041 created "2016-06-24" @default.
• W2071299041 creator A5000039714 @default.
• W2071299041 creator A5005513572 @default.
• W2071299041 creator A5014511134 @default.
• W2071299041 creator A5018988703 @default.
• W2071299041 creator A5023664422 @default.
• W2071299041 creator A5026892123 @default.
• W2071299041 creator A5027634811 @default.
• W2071299041 creator A5030132143 @default.
• W2071299041 creator A5043035754 @default.
• W2071299041 creator A5060792245 @default.
• W2071299041 creator A5073488277 @default.
• W2071299041 creator A5078461170 @default.
• W2071299041 creator A5079302927 @default.
• W2071299041 creator A5085547862 @default.
• W2071299041 creator A5086687503 @default.
• W2071299041 date "2014-05-01" @default.
• W2071299041 modified "2023-10-18" @default.
• W2071299041 title "Safety and efficacy of uric acid in patients with acute stroke (URICO-ICTUS): a randomised, double-blind phase 2b/3 trial" @default.
• W2071299041 cites W1479785033 @default.
• W2071299041 cites W1968367657 @default.
• W2071299041 cites W1969661146 @default.
• W2071299041 cites W1986583210 @default.
• W2071299041 cites W1997064745 @default.
• W2071299041 cites W2007847945 @default.
• W2071299041 cites W2013813451 @default.
• W2071299041 cites W2018782821 @default.
• W2071299041 cites W2023166851 @default.
• W2071299041 cites W2025372788 @default.
• W2071299041 cites W2048365284 @default.
• W2071299041 cites W2050856345 @default.
• W2071299041 cites W2054441747 @default.
• W2071299041 cites W2078904393 @default.
• W2071299041 cites W2098032054 @default.
• W2071299041 cites W2102182027 @default.
• W2071299041 cites W2105534568 @default.
• W2071299041 cites W2107419879 @default.
• W2071299041 cites W2109663185 @default.
• W2071299041 cites W2136280619 @default.
• W2071299041 cites W2156442792 @default.
• W2071299041 cites W2157595656 @default.
• W2071299041 cites W2159233098 @default.
• W2071299041 cites W2161273579 @default.
• W2071299041 cites W2292308933 @default.
• W2071299041 cites W4292022394 @default.
• W2071299041 doi "https://doi.org/10.1016/s1474-4422(14)70054-7" @default.
• W2071299041 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24703208" @default.
• W2071299041 hasPublicationYear "2014" @default.
• W2071299041 type Work @default.
• W2071299041 sameAs 2071299041 @default.
• W2071299041 citedByCount "206" @default.
• W2071299041 countsByYear W20712990412014 @default.
• W2071299041 countsByYear W20712990412015 @default.
• W2071299041 countsByYear W20712990412016 @default.
• W2071299041 countsByYear W20712990412017 @default.
• W2071299041 countsByYear W20712990412018 @default.
• W2071299041 countsByYear W20712990412019 @default.
• W2071299041 countsByYear W20712990412020 @default.
• W2071299041 countsByYear W20712990412021 @default.
• W2071299041 countsByYear W20712990412022 @default.
• W2071299041 countsByYear W20712990412023 @default.
• W2071299041 crossrefType "journal-article" @default.
• W2071299041 hasAuthorship W2071299041A5000039714 @default.
• W2071299041 hasAuthorship W2071299041A5005513572 @default.
• W2071299041 hasAuthorship W2071299041A5014511134 @default.
• W2071299041 hasAuthorship W2071299041A5018988703 @default.
• W2071299041 hasAuthorship W2071299041A5023664422 @default.
• W2071299041 hasAuthorship W2071299041A5026892123 @default.
• W2071299041 hasAuthorship W2071299041A5027634811 @default.
• W2071299041 hasAuthorship W2071299041A5030132143 @default.
• W2071299041 hasAuthorship W2071299041A5043035754 @default.
• W2071299041 hasAuthorship W2071299041A5060792245 @default.
• W2071299041 hasAuthorship W2071299041A5073488277 @default.
• W2071299041 hasAuthorship W2071299041A5078461170 @default.
• W2071299041 hasAuthorship W2071299041A5079302927 @default.
• W2071299041 hasAuthorship W2071299041A5085547862 @default.
• W2071299041 hasAuthorship W2071299041A5086687503 @default.
• W2071299041 hasConcept C126322002 @default.
• W2071299041 hasConcept C127413603 @default.
• W2071299041 hasConcept C142724271 @default.
• W2071299041 hasConcept C168563851 @default.
• W2071299041 hasConcept C1862650 @default.
• W2071299041 hasConcept C204787440 @default.
• W2071299041 hasConcept C27081682 @default.
• W2071299041 hasConcept C2779881121 @default.
• W2071299041 hasConcept C2780645631 @default.
• W2071299041 hasConcept C2780931571 @default.
• W2071299041 hasConcept C2908647359 @default.
• W2071299041 hasConcept C3020199598 @default.
• W2071299041 hasConcept C541997718 @default.
• W2071299041 hasConcept C71924100 @default.
• W2071299041 hasConcept C78519656 @default.
• W2071299041 hasConcept C99454951 @default.
• W2071299041 hasConceptScore W2071299041C126322002 @default.
• W2071299041 hasConceptScore W2071299041C127413603 @default.
• W2071299041 hasConceptScore W2071299041C142724271 @default.
• W2071299041 hasConceptScore W2071299041C168563851 @default.

• next